Wasatch Advisors Inc. acquired a new stake in Glaukos Corp (NYSE:GKOS) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 25,771 shares of the medical instruments supplier’s stock, valued at approximately $661,000.
Several other hedge funds have also recently bought and sold shares of the stock. California Public Employees Retirement System raised its holdings in shares of Glaukos by 10.5% in the 2nd quarter. California Public Employees Retirement System now owns 8,400 shares of the medical instruments supplier’s stock valued at $348,000 after buying an additional 800 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Glaukos by 1.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 70,313 shares of the medical instruments supplier’s stock valued at $2,915,000 after buying an additional 994 shares during the period. Ameritas Investment Partners Inc. raised its holdings in shares of Glaukos by 93.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 1,212 shares during the period. GSA Capital Partners LLP raised its holdings in shares of Glaukos by 3.7% in the 2nd quarter. GSA Capital Partners LLP now owns 35,080 shares of the medical instruments supplier’s stock valued at $1,455,000 after buying an additional 1,237 shares during the period. Finally, Navellier & Associates Inc raised its holdings in shares of Glaukos by 4.9% in the 2nd quarter. Navellier & Associates Inc now owns 33,307 shares of the medical instruments supplier’s stock valued at $1,381,000 after buying an additional 1,567 shares during the period. Hedge funds and other institutional investors own 99.23% of the company’s stock.
Shares of Glaukos Corp (NYSE GKOS) opened at $28.54 on Friday. Glaukos Corp has a 1-year low of $23.08 and a 1-year high of $52.49. The firm has a market capitalization of $986.49, a PE ratio of 237.83, a price-to-earnings-growth ratio of 41.36 and a beta of 1.02.
In related news, CFO Joseph E. Gilliam purchased 2,100 shares of the business’s stock in a transaction on Wednesday, November 22nd. The shares were bought at an average price of $23.84 per share, for a total transaction of $50,064.00. Following the acquisition, the chief financial officer now directly owns 102,100 shares in the company, valued at $2,434,064. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 16.40% of the stock is owned by corporate insiders.
Several research firms recently issued reports on GKOS. BMO Capital Markets reiterated a “buy” rating on shares of Glaukos in a report on Monday, December 11th. Cantor Fitzgerald set a $48.00 price objective on Glaukos and gave the company a “buy” rating in a report on Wednesday, January 10th. Zacks Investment Research upgraded Glaukos from a “sell” rating to a “hold” rating in a report on Monday, November 13th. Finally, Stephens reiterated an “overweight” rating and issued a $40.00 price objective (down previously from $47.00) on shares of Glaukos in a report on Monday, November 13th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $44.86.
TRADEMARK VIOLATION WARNING: “25,771 Shares in Glaukos Corp (GKOS) Acquired by Wasatch Advisors Inc.” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3148741/25771-shares-in-glaukos-corp-gkos-acquired-by-wasatch-advisors-inc.html.
Glaukos Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corp (NYSE:GKOS).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.